Glaucoma secondary to spherophakia/ectopia lentis and megalocornea

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:238763OMIM:251750Q15.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Glaucoma secondary to spherophakia/ectopia lentis and megalocornea (Orphanet code 238763) is a rare inherited ocular disorder characterized by the combination of an abnormally spherical lens (spherophakia), displacement of the lens from its normal position (ectopia lentis), and an enlarged cornea (megalocornea), which together predispose the eye to the development of secondary glaucoma. The condition primarily affects the anterior segment of the eye. Spherophakia causes the lens to become more rounded and smaller than normal, which can lead to pupillary block as the abnormal lens pushes forward, obstructing the flow of aqueous humor between the posterior and anterior chambers. This obstruction results in elevated intraocular pressure and secondary angle-closure glaucoma. Megalocornea, defined as a corneal diameter greater than 13 mm, further contributes to structural abnormalities of the anterior chamber. Ectopia lentis may cause visual disturbances including significant refractive errors and can worsen the mechanical obstruction of aqueous outflow. Patients typically present with decreased visual acuity, eye pain, and progressive visual field loss if glaucoma is not adequately managed. The condition may occur as an isolated ocular finding or in association with systemic connective tissue disorders such as Marfan syndrome, Weill-Marchesani syndrome, or homocystinuria, where lens abnormalities are a recognized feature. Diagnosis is made through comprehensive ophthalmic examination including slit-lamp biomicroscopy, gonioscopy, measurement of intraocular pressure, and assessment of corneal diameter. Treatment focuses on controlling intraocular pressure through medical therapy (topical and systemic anti-glaucoma medications, including miotics or cycloplegics depending on the mechanism), laser iridotomy to relieve pupillary block, and surgical intervention when necessary, which may include lensectomy (removal of the displaced lens), glaucoma filtering surgery, or combined procedures. Early detection and management are critical to prevent irreversible optic nerve damage and vision loss.

Also known as:

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Glaucoma secondary to spherophakia/ectopia lentis and megalocornea.

View clinical trials →

No actively recruiting trials found for Glaucoma secondary to spherophakia/ectopia lentis and megalocornea at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Glaucoma secondary to spherophakia/ectopia lentis and megalocornea community →

No specialists are currently listed for Glaucoma secondary to spherophakia/ectopia lentis and megalocornea.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Glaucoma secondary to spherophakia/ectopia lentis and megalocornea.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Glaucoma secondary to spherophakia/ectopia lentis and megalocorneaForum →

No community posts yet. Be the first to share your experience with Glaucoma secondary to spherophakia/ectopia lentis and megalocornea.

Start the conversation →

Latest news about Glaucoma secondary to spherophakia/ectopia lentis and megalocornea

No recent news articles for Glaucoma secondary to spherophakia/ectopia lentis and megalocornea.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Glaucoma secondary to spherophakia/ectopia lentis and megalocornea

What is Glaucoma secondary to spherophakia/ectopia lentis and megalocornea?

Glaucoma secondary to spherophakia/ectopia lentis and megalocornea (Orphanet code 238763) is a rare inherited ocular disorder characterized by the combination of an abnormally spherical lens (spherophakia), displacement of the lens from its normal position (ectopia lentis), and an enlarged cornea (megalocornea), which together predispose the eye to the development of secondary glaucoma. The condition primarily affects the anterior segment of the eye. Spherophakia causes the lens to become more rounded and smaller than normal, which can lead to pupillary block as the abnormal lens pushes forwar